{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T03:16:41Z","timestamp":1782184601297,"version":"3.54.5"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T00:00:00Z","timestamp":1727827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T00:00:00Z","timestamp":1727827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose of Review<\/jats:title>\n                <jats:p>Pediatric healthcare providers have increasingly become aware of the need for timely and informative transition of adolescents and young adults with chronic medical conditions such as diabetes and cystic fibrosis. However, there is paucity of published data on the importance of and most effective way to transition youth with lipid disorders who are at increased risk of premature cardiovascular disease.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Recent Findings<\/jats:title>\n                <jats:p>Evidence shows that atherosclerosis begins at a young age. However, there are no guidelines on the transition of adolescents and young adults with dyslipidemia. In addition, there are conflicting guidelines for lipid management in children versus adults, despite advances in medical pharmacotherapies for dyslipidemia.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Summary<\/jats:title>\n                <jats:p>The lack of guidelines for transition and discordant recommendations for management of this vulnerable population places young adults at-risk for worsening of their underlying disease, and premature cardiovascular events.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11883-024-01244-0","type":"journal-article","created":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T09:02:01Z","timestamp":1727859721000},"page":"693-700","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Transitioning Adolescents and Young Adults with Lipid Disorders to Adult Health Care"],"prefix":"10.1007","volume":"26","author":[{"given":"Christopher","family":"Schmitt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Yohannan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,2]]},"reference":[{"issue":"2","key":"1244_CR1","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.3390\/ijms24021366","volume":"24","author":"R Fiorentino","year":"2023","unstructured":"Fiorentino R, Chiarelli F. Statins in children, an update. Int J Mol Sci. 2023;24(2):1366. https:\/\/doi.org\/10.3390\/ijms24021366. Published 2023 Jan 10.","journal-title":"Int J Mol Sci"},{"issue":"21","key":"1244_CR2","doi-asserted-by":"publisher","first-page":"4291","DOI":"10.3390\/ijerph16214291","volume":"16","author":"M Ratajczak","year":"2019","unstructured":"Ratajczak M, Skrypnik D, Bogda\u0144ski P, et al. Effects of endurance and endurance-strength training on endothelial function in women with obesity: a randomized trial. Int J Environ Res Public Health. 2019;16(21):4291. https:\/\/doi.org\/10.3390\/ijerph16214291. Published 2019 Nov.","journal-title":"Int J Environ Res Public Health"},{"issue":"3","key":"1244_CR3","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.3928\/19382359-20210218-01","volume":"50","author":"S Leopold","year":"2021","unstructured":"Leopold S, Zachariah JP. Pediatric lipid disorders. Pediatr Ann. 2021;50(3):e105\u201312. https:\/\/doi.org\/10.3928\/19382359-20210218-01.","journal-title":"Pediatr Ann"},{"issue":"10","key":"1244_CR4","doi-asserted-by":"publisher","first-page":"4421","DOI":"10.1210\/jc.2019-00150","volume":"104","author":"AP Ashraf","year":"2019","unstructured":"Ashraf AP, Kohn B, Wilson DP. Improving long-term outcomes of youth with lipid abnormalities-expanding the role of pediatric endocrinologists. J Clin Endocrinol Metab. 2019;104(10):4421\u20136. https:\/\/doi.org\/10.1210\/jc.2019-00150.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"1244_CR5","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1016\/j.cjca.2020.03.020","volume":"36","author":"J Lazarte","year":"2020","unstructured":"Lazarte J, Hegele RA. Pediatric dyslipidemia-beyond familial hypercholesterolemia. Can J Cardiol. 2020;36(9):1362\u201371. https:\/\/doi.org\/10.1016\/j.cjca.2020.03.020.","journal-title":"Can J Cardiol"},{"issue":"8","key":"1244_CR6","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1542\/pir.2019-0053","volume":"41","author":"J Stewart","year":"2020","unstructured":"Stewart J, McCallin T, Martinez J, Chacko S, Yusuf S. Hyperlipidemia. Pediatr Rev. 2020;41(8):393\u2013402. https:\/\/doi.org\/10.1542\/pir.2019-0053.","journal-title":"Pediatr Rev"},{"issue":"3","key":"1244_CR7","doi-asserted-by":"publisher","first-page":"817","DOI":"10.31083\/j.rcm2203088","volume":"22","author":"AV Burlutskaya","year":"2021","unstructured":"Burlutskaya AV, Tril VE, Polischuk LV, Pokrovskii VM. Dyslipidemia in pediatrician\u2019s practice. Rev Cardiovasc Med. 2021;22(3):817\u201334. https:\/\/doi.org\/10.31083\/j.rcm2203088.","journal-title":"Rev Cardiovasc Med"},{"issue":"9","key":"1244_CR8","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/j.cjca.2020.05.035","volume":"36","author":"M Khoury","year":"2020","unstructured":"Khoury M, Rodday AM, Mackie AS, et al. Pediatric lipid screening and treatment in Canada: practices, attitudes, and barriers. Can J Cardiol. 2020;36(9):1545\u20139. https:\/\/doi.org\/10.1016\/j.cjca.2020.05.035.","journal-title":"Can J Cardiol"},{"issue":"9","key":"1244_CR9","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1016\/j.cjca.2020.05.041","volume":"36","author":"RJ Chung","year":"2020","unstructured":"Chung RJ, Mackie AS, Baker A, de Ferranti SD. Cardiovascular risk and cardiovascular health behaviours in the transition from childhood to adulthood. Can J Cardiol. 2020;36(9):1448\u201357. https:\/\/doi.org\/10.1016\/j.cjca.2020.05.041.","journal-title":"Can J Cardiol"},{"issue":"6","key":"1244_CR10","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1001\/jamapediatrics.2015.0168","volume":"169","author":"HC Gooding","year":"2015","unstructured":"Gooding HC, Rodday AM, Wong JB, et al. Application of pediatric and adult guidelines for treatment of lipid levels among us adolescents transitioning to young adulthood. JAMA Pediatr. 2015;169(6):569\u201374. https:\/\/doi.org\/10.1001\/jamapediatrics.2015.0168.","journal-title":"JAMA Pediatr"},{"issue":"8","key":"1244_CR11","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s11883-023-01122-1","volume":"25","author":"GK Kim","year":"2023","unstructured":"Kim GK, Yee JK, Bansal N. Algorithms for treating dyslipidemia in youth. Curr Atheroscler Rep. 2023;25(8):495\u2013507. https:\/\/doi.org\/10.1007\/s11883-023-01122-1.","journal-title":"Curr Atheroscler Rep"},{"key":"1244_CR12","doi-asserted-by":"publisher","unstructured":"Grundy SM, Stone NJ, Bailey AL, et al. AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines [published correction appears in Circulation. 2019 Jun 18;139(25):e1182-e1186] [published correction appears in Circulation. 2023 Aug 15;148(7):e5].\u00a0Circulation. 2019;139(25):e1082-e1143. https:\/\/doi.org\/10.1161\/CIR.0000000000000625.","DOI":"10.1161\/CIR.0000000000000625"},{"issue":"4","key":"1244_CR13","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1097\/MOL.0000000000000879","volume":"34","author":"P Choudhari","year":"2023","unstructured":"Choudhari P, Patni N. Updates in the management of pediatric dyslipidemia. Curr Opin Lipidol. 2023;34(4):156\u201361. https:\/\/doi.org\/10.1097\/MOL.0000000000000879.","journal-title":"Curr Opin Lipidol"},{"issue":"25","key":"1244_CR14","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1093\/eurheartj\/ehad197","volume":"44","author":"M Cuchel","year":"2023","unstructured":"Cuchel M, Raal FJ, Hegele RA, et al. 2023 update on European atherosclerosis society consensus statement on homozygous familial hypercholesterolaemia: new treatments and clinical guidance. Eur Heart J. 2023;44(25):2277\u201391. https:\/\/doi.org\/10.1093\/eurheartj\/ehad197.","journal-title":"Eur Heart J"},{"issue":"10326","key":"1244_CR15","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/S0140-6736(21)02001-8","volume":"399","author":"TR Tromp","year":"2022","unstructured":"Tromp TR, Hartgers ML, Hovingh GK, et al. Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study. Lancet. 2022;399(10326):719\u201328. https:\/\/doi.org\/10.1016\/S0140-6736(21)02001-8.","journal-title":"Lancet"},{"issue":"5","key":"1244_CR16","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.3390\/biomedicines10051043","volume":"10","author":"F Mainieri","year":"2022","unstructured":"Mainieri F, Tagi VM, Chiarelli F. Recent advances on familial hypercholesterolemia in children and adolescents. Biomedicines. 2022;10(5):1043. https:\/\/doi.org\/10.3390\/biomedicines10051043. Published 2022 Apr.","journal-title":"Biomedicines"},{"issue":"14","key":"1244_CR17","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa2019910","volume":"383","author":"RD Santos","year":"2020","unstructured":"Santos RD, Ruzza A, Hovingh GK, et al. Evolocumab in pediatric heterozygous familial hypercholesterolemia. N Engl J Med. 2020;383(14):1317\u201327. https:\/\/doi.org\/10.1056\/NEJMoa2019910.","journal-title":"N Engl J Med"},{"issue":"5","key":"1244_CR18","doi-asserted-by":"publisher","first-page":"422","DOI":"10.5551\/jat.42242","volume":"25","author":"M Harada-Shiba","year":"2018","unstructured":"Harada-Shiba M, Kastelein JJP, Hovingh GK, et al. Efficacy and safety of Pitavastatin in children and adolescents with familial hypercholesterolemia in Japan and Europe. J Atheroscler Thromb. 2018;25(5):422\u20139. https:\/\/doi.org\/10.5551\/jat.42242.","journal-title":"J Atheroscler Thromb"},{"issue":"1","key":"1244_CR19","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.jacl.2016.11.001","volume":"11","author":"SK Sliwinski","year":"2017","unstructured":"Sliwinski SK, Gooding H, de Ferranti S, et al. Transitioning from pediatric to adult health care with familial hypercholesterolemia: listening to young adult and parent voices. J Clin Lipidol. 2017;11(1):147\u201359. https:\/\/doi.org\/10.1016\/j.jacl.2016.11.001.","journal-title":"J Clin Lipidol"},{"issue":"1","key":"1244_CR20","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12944-020-01218-6","volume":"19","author":"M Brzezi\u0144ski","year":"2020","unstructured":"Brzezi\u0144ski M, Metelska P, My\u015bliwiec M, Szlagatys-Sidorkiewicz A. Lipid disorders in children living with overweight and obesity- large cohort study from Poland. Lipids Health Dis. 2020;19(1):47. https:\/\/doi.org\/10.1186\/s12944-020-01218-6. Published 2020 Mar 16.","journal-title":"Lipids Health Dis"},{"issue":"14","key":"1244_CR21","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1093\/eurjpc\/zwad204","volume":"30","author":"PL Valenzuela","year":"2023","unstructured":"Valenzuela PL, Santos-Lozano A, Saco-Ledo G, Castillo-Garc\u00eda A, Lucia A. Obesity, cardiovascular risk, and lifestyle: cross-sectional and prospective analyses in a nationwide Spanish cohort. Eur J Prev Cardiol. 2023;30(14):1493\u2013501. https:\/\/doi.org\/10.1093\/eurjpc\/zwad204.","journal-title":"Eur J Prev Cardiol"},{"issue":"4","key":"1244_CR22","doi-asserted-by":"publisher","first-page":"241","DOI":"10.5114\/pedm.2022.122050","volume":"28","author":"M W\u00f3jcik","year":"2022","unstructured":"W\u00f3jcik M. Lipid disorders in children - an underestimated problem. Pediatr Endocrinol Diabetes Metab. 2022;28(4):241\u20134. https:\/\/doi.org\/10.5114\/pedm.2022.122050.","journal-title":"Pediatr Endocrinol Diabetes Metab"},{"issue":"3","key":"1244_CR23","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1001\/jama.2023.8867","volume":"330","author":"JM Guirguis-Blake","year":"2023","unstructured":"Guirguis-Blake JM, Evans CV, Coppola EL, Redmond N, Perdue LA. Screening for lipid disorders in children and adolescents: updated evidence report and systematic review for the us preventive services task force. JAMA. 2023;330(3):261\u201374. https:\/\/doi.org\/10.1001\/jama.2023.8867.","journal-title":"JAMA"},{"issue":"12","key":"1244_CR24","doi-asserted-by":"publisher","first-page":"3605","DOI":"10.1210\/clinem\/dgab568","volume":"106","author":"AP Ashraf","year":"2021","unstructured":"Ashraf AP, Sunil B, Bamba V, et al. Case studies in pediatric lipid disorders and their management. J Clin Endocrinol Metab. 2021;106(12):3605\u201320. https:\/\/doi.org\/10.1210\/clinem\/dgab568.","journal-title":"J Clin Endocrinol Metab"},{"key":"1244_CR25","doi-asserted-by":"publisher","unstructured":"Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents, National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report.\u00a0Pediatrics. 2011;128 Suppl 5(Suppl 5):S213-S256. https:\/\/doi.org\/10.1542\/peds.2009-2107C.","DOI":"10.1542\/peds.2009-2107C"},{"issue":"5","key":"1244_CR26","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s11883-022-01013-x","volume":"24","author":"WZ Butt","year":"2022","unstructured":"Butt WZ, Yee JK. The role of non-statin lipid-lowering medications in youth with hypercholesterolemia. Curr Atheroscler Rep. 2022;24(5):379\u201389. https:\/\/doi.org\/10.1007\/s11883-022-01013-x.","journal-title":"Curr Atheroscler Rep"},{"issue":"12","key":"1244_CR27","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1161\/ATVBAHA.122.317793","volume":"42","author":"E Bruckert","year":"2022","unstructured":"Bruckert E, Caprio S, Wiegman A, et al. Efficacy and safety of alirocumab in children and adolescents with homozygous familial hypercholesterolemia: phase 3, multinational open-label study. Arterioscler Thromb Vasc Biol. 2022;42(12):1447\u201357. https:\/\/doi.org\/10.1161\/ATVBAHA.122.317793.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"12","key":"1244_CR28","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1161\/ATVBAHA.122.318598","volume":"42","author":"SS Gidding","year":"2022","unstructured":"Gidding SS, Hegele RA. Introducing personalized medicine into pediatric homozygous familial hypercholesterolemia care. Arterioscler Thromb Vasc Biol. 2022;42(12):1458\u201360. https:\/\/doi.org\/10.1161\/ATVBAHA.122.318598.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"10","key":"1244_CR29","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/S2213-8587(22)00221-2","volume":"10","author":"RD Santos","year":"2022","unstructured":"Santos RD, Ruzza A, Hovingh GK, et al. Paediatric patients with heterozygous familial hypercholesterolaemia treated with evolocumab for 80 weeks (HAUSER-OLE): a single-arm, multicentre, open-label extension of HAUSER-RCT. Lancet Diabetes Endocrinol. 2022;10(10):732\u201340. https:\/\/doi.org\/10.1016\/S2213-8587(22)00221-2.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"1244_CR30","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1001\/jamapediatrics.2023.6477","volume":"178","author":"RD Santos","year":"2024","unstructured":"Santos RD, Wiegman A, Caprio S, et al. Alirocumab in pediatric patients with heterozygous familial hypercholesterolemia: a randomized clinical trial. JAMA Pediatr. 2024;178(3):283\u201393. https:\/\/doi.org\/10.1001\/jamapediatrics.2023.6477.","journal-title":"JAMA Pediatr"},{"issue":"9","key":"1244_CR31","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1093\/eurjpc\/zwac025","volume":"29","author":"MD Reijman","year":"2022","unstructured":"Reijman MD, Schweizer A, Peterson ALH, et al. Rationale and design of two trials assessing the efficacy, safety, and tolerability of inclisiran in adolescents with homozygous and heterozygous familial hypercholesterolaemia. Eur J Prev Cardiol. 2022;29(9):1361\u20138. https:\/\/doi.org\/10.1093\/eurjpc\/zwac025.","journal-title":"Eur J Prev Cardiol"},{"issue":"2","key":"1244_CR32","doi-asserted-by":"publisher","first-page":"101427","DOI":"10.1016\/j.dhjo.2022.101427","volume":"16","author":"B Hopson","year":"2023","unstructured":"Hopson B, Eckenrode M, Rocque BG, et al. The development of a transition medical home utilizing the individualized transition plan (ITP) model for patients with complex diseases of childhood. Disabil Health J. 2023;16(2):101427. https:\/\/doi.org\/10.1016\/j.dhjo.2022.101427.","journal-title":"Disabil Health J"},{"issue":"8","key":"1244_CR33","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1007\/s00246-023-03292-w","volume":"44","author":"V Kieu","year":"2023","unstructured":"Kieu V, Sumski C, Cohen S, Reinhardt E, Axelrod DM, Handler SS. The use of virtual reality learning on transition education in adolescents with congenital heart disease. Pediatr Cardiol. 2023;44(8):1856\u201360. https:\/\/doi.org\/10.1007\/s00246-023-03292-w.","journal-title":"Pediatr Cardiol"},{"issue":"12","key":"1244_CR34","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1089\/thy.2022.0407","volume":"32","author":"M Goldfarb","year":"2022","unstructured":"Goldfarb M, Franco AT. Survivorship, quality of life, and transition to adult care for pediatric and adolescent thyroid cancer survivors. Thyroid. 2022;32(12):1471\u20136. https:\/\/doi.org\/10.1089\/thy.2022.0407.","journal-title":"Thyroid"},{"issue":"5","key":"1244_CR35","doi-asserted-by":"publisher","first-page":"e63","DOI":"10.1016\/j.pedn.2015.01.025","volume":"30","author":"L Hays","year":"2015","unstructured":"Hays L. Transition to adult congenital heart disease care: a review. J Pediatr Nurs. 2015;30(5):e63\u20139. https:\/\/doi.org\/10.1016\/j.pedn.2015.01.025.","journal-title":"J Pediatr Nurs"},{"issue":"9385","key":"1244_CR36","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/S0140-6736(03)14234-1","volume":"362","author":"P Durrington","year":"2003","unstructured":"Durrington P. Dyslipidaemia. Lancet. 2003;362(9385):717\u201331. https:\/\/doi.org\/10.1016\/S0140-6736(03)14234-1.","journal-title":"Lancet"},{"key":"1244_CR37","doi-asserted-by":"publisher","unstructured":"Stone NJ, Robinson JG, Lichtenstein AH, et al. ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines [published correction appears in J Am Coll Cardiol. 2014 Jul 1;63(25 Pt B):3024\u20133025] [published correction appears in J Am Coll Cardiol. 2015 Dec 22;66(24):2812].\u00a0J Am Coll Cardiol. 2014;63(25 Pt B):2889\u20132934. https:\/\/doi.org\/10.1016\/j.jacc.2013.11.002.","DOI":"10.1016\/j.jacc.2013.11.002"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-024-01244-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-024-01244-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-024-01244-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T05:08:59Z","timestamp":1730437739000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11883-024-01244-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,2]]},"references-count":37,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["1244"],"URL":"https:\/\/doi.org\/10.1007\/s11883-024-01244-0","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,2]]},"assertion":[{"value":"23 September 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"No animal or human subjects by the authors were used in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}